|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:affiliatedWith
|
monoclonal antibodies
EGFR inhibitors
|
|
gptkbp:alternativeName
|
h-R3
|
|
gptkbp:approvedBy
|
gptkb:nasopharyngeal_carcinoma
gptkb:Algeria
gptkb:Argentina
gptkb:Colombia
gptkb:Cuba
gptkb:India
gptkb:Indonesia
gptkb:Mexico
gptkb:Peru
gptkb:Philippines
gptkb:Thailand
gptkb:Ukraine
2002
esophageal cancer
pancreatic cancer
head and neck cancer
glioma
|
|
gptkbp:ATCCode
|
L01XC
|
|
gptkbp:CASNumber
|
406726-75-6
|
|
gptkbp:clinicalTrialPhase
|
Phase III
|
|
gptkbp:compatibleWith
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:developedBy
|
gptkb:Cuba
Center of Molecular Immunology
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
nimotuzumab
|
|
gptkbp:indication
|
solid tumors
esophageal squamous cell carcinoma
adult glioblastoma
pediatric glioma
|
|
gptkbp:macromoleculeType
|
gptkb:EGFR
|
|
gptkbp:marketedAs
|
gptkb:Biocon
gptkb:CIMAB_S.A.
Inno Biologics
|
|
gptkbp:mechanismOfAction
|
EGFR inhibition
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
fatigue
rash
infusion reaction
|
|
gptkbp:target
|
gptkb:epidermal_growth_factor_receptor
|
|
gptkbp:type
|
humanized antibody
|
|
gptkbp:UNII
|
6Z5B6HVF6O
|
|
gptkbp:usedFor
|
gptkb:cancer
|
|
gptkbp:bfsParent
|
gptkb:EGFR_inhibitors_(in_colorectal_cancer)
gptkb:HGNC:3689
gptkb:HGNC:3767
|
|
gptkbp:bfsLayer
|
7
|